ENTRADA THERAPEUTICS INC (TRDA)
Health Care · Clinical-stage genetic medicines and oligonucleotide therapeutics · NASDAQ
Entrada is a clinical-stage biotech advancing exon-skipping genetic medicines with proprietary endosomal escape technology to treat neuromuscular diseases like DMD, with multiple programs in Phase 1/2 trials and an partnership with Vertex on a DM1 therapy.
What ENTRADA THERAPEUTICS INC does
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to engage intracellular targets that have historically been inaccessible. The company is advancing a robust portfolio of exon-skipping therapies targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as inherited retinal diseases including Usher syndrome, utilizing proprietary endosomal escape technology and oligonucleotide-based approaches.
Themes: ["Duchenne muscular dystrophy (DMD)","Myotonic dystrophy type 1 (DM1)","Inherited retinal diseases","Genetic medicines","Exon-skipping / splice modulation","Rare pediatric diseases","Neuromuscular disorders"]
Fundamentals
- Price$7.40 as of 2026-07-09 close
- Market cap$287M as of 2026-07-10
- 1-year return+2.2% as of 2026-07-09 close
- Net margin-2895.1% as of 2026-07-10
- ROE-51.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-96.7% as of 2026-07-10
- Revenue CAGR (3y)-55.6% SEC XBRL
- Beta-0.29 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products and no revenue; success depends entirely on clinical trial outcomes and regulatory approval of experimental programs, with substantial uncertainty as to whether any candidate will ever reach commercialization.","Intensive cash burn ($254.9M in cash and equivalents as of Q1 2026 projected to fund operations only into Q3 2027) creates significant financing risk and dilution potential if additional capital is required.","Dependence on partnerships (notably Vertex for VX-670) and regulatory pathways; delays, failures, or adverse data from any clinical program could materially impair the company's value and future prospects."]
Competitors & peers
- Sarepta Therapeutics (SRPT)
- Vertex Pharmaceuticals (VTEX)
- Exonics Therapeutics
- ProQR Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.